Vanguard Personalized Indexing Management
ALNY icon

Vanguard Personalized Indexing Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Sell
11,436
-779
-6% -$235K 0.03% 455
2026
Q1 		$4.04M Sell
12,215
-1,512
-11% -$515K 0.04% 370
2025
Q4 		$5.46M Sell
13,727
-258
-2% -$114K 0.05% 284
2025
Q3 		$6.38M Buy
13,985
+595
+4% +$242K 0.07% 251
2025
Q2 		$4.37M Buy
13,390
+4,302
+47% +$1.19M 0.05% 331
2025
Q1 		$2.45M Buy
9,088
+514
+6% +$132K 0.04% 422
2024
Q4 		$2.02M Sell
8,574
-404
-4% -$106K 0.03% 477
2024
Q3 		$2.47M Buy
8,978
+1,825
+26% +$475K 0.04% 397
2024
Q2 		$1.74M Buy
7,153
+1,067
+18% +$168K 0.03% 454
2024
Q1 		$910K Sell
6,086
-304
-5% -$50.7K 0.02% 711
2023
Q4 		$1.22M Buy
6,390
+655
+11% +$112K 0.03% 534
2023
Q3 		$1.02M Sell
5,735
-623
-10% -$119K 0.03% 552
2023
Q2 		$1.21M Buy
6,358
+59
+0.9% +$11.7K 0.04% 480
2023
Q1 		$1.26M Sell
6,299
-293
-4% -$61.6K 0.04% 429
2022
Q4 		$1.57M Buy
6,592
+726
+12% +$155K 0.06% 340
2022
Q3 		$1.17M Buy
5,866
+1,398
+31% +$267K 0.05% 411
2022
Q2 		$652K Buy
4,468
+275
+7% +$39K 0.03% 684
2022
Q1 		$685K Buy
4,193
+1,304
+45% +$199K 0.03% 661
2021
Q4 		$490K Buy
2,889
+438
+18% +$81.4K 0.03% 707
2021
Q3 		$463K Buy
2,451
+222
+10% +$41.6K 0.04% 553
2021
Q2 		$378K Buy
+2,229
New +$326K 0.04% 626

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's ALNY Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.4% in Q2 2026, selling an estimated $235K and leaving 11,436 shares worth $3.44M. The position accounts for 0.03% of the portfolio, ranked #455.

Vanguard Personalized Indexing Management first reported a position in ALNY in Q2 2021 and has held it in 21 quarters since. The position peaked at $6.38M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vanguard Personalized Indexing Management held 11,436 shares of Alnylam Pharmaceuticals worth $3.44M as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 779 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $235K.
  • Alnylam Pharmaceuticals made up 0.03% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #455 holding.
  • Vanguard Personalized Indexing Management first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Vanguard Personalized Indexing Management's Alnylam Pharmaceuticals position peaked at $6.38M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.